



OXiGENE to Present at Friedman Billings Ramsey Ninth Annual Growth Conference: June 1st at 11am

WALTHAM, Mass.--(BUSINESS WIRE)--May 27, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular neovascular diseases, today announced that President and Chief Executive Officer Fred Driscoll will present an overview of the Company at the Friedman Billings Ramsey Ninth Annual Growth Conference on June 1st at 11:00 am ET.

The presentation will be available live via webcast on OXiGENE's website, www.oxigene.com. The presentation will be available via archive beginning two hours after the presentation. To access the webcast from the OXiGENE home page, click on the "Calendar of Events" link under the tab labeled "Press Room". Please log on five minutes prior to the event to ensure the proper software is downloaded and installed.

About OXiGENE, Inc.

OXiGENE is an emerging pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

CONTACT: OXiGENE Inc.
James Murphy, 781-547-5900
Vice President and CFO
jmurphy@oxigene.com
or
MacDougall BioCommunications
Chris Erdman, 508-647-0209
Vice President
chris@macbiocom.com

SOURCE: OXiGENE, Inc.